AN2 Therapeutics, Inc.
NASDAQ:ANTXBiotechnology
+$0.04 today
- Market cap
- $187.82M
- Beta
- -0.98
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$1.01
Volume 0.97M
Average 0.29M
ANTX Tax Assets
Deferred tax assets that can reduce taxes payable in future periods.
AN2 Therapeutics, Inc.NASDAQ: ANTX
Tax Assets · Q1 FY2026 · quarter ended Mar 2026
Tax assets remains negative
Q1 FY2026 tax assets was $0, compared with $0 a year earlier.
Context
- Tax assets amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Tax assets increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Tax Assets history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Tax Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Tax Assets vs competitors
How ANTX compares with its peers on the latest reported figures
- ANTX's Mar 2026 tax assets of $0 is the highest of the 6 companies compared; the peer median is $0.
- Tax assets amounts to 0.0% of total assets for ANTX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ANTX) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for ANTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 12.1M | 27.22M | 15.65M | 21.35M | 19.94M |
| Short-term Investments | 46.46M | 68.84M | 91.65M | 62.27M | 38.06M |
| Net Receivables | 0 | 0 | 1.4M | 300K | 900K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.55M | 2.56M | 3.21M | 2.34M | 1.04M |
| Total Current Assets | 60.11M | 98.62M | 110.51M | 86.26M | 59.94M |
| Property, Plant & Equipment (Net) | 0 | 53K | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 3.49M | 3.22M | 27.19M | 5.02M | 2.01M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.72M | 667K | 1.04M | 804K | 0 |
| Total Non-current Assets | 5.21M | 3.94M | 28.24M | 5.83M | 2.01M |
| Total Assets | 65.32M | 102.56M | 138.74M | 92.09M | 61.95M |
| Account Payables | 1.06M | 2.12M | 2.68M | 3.32M | 3.02M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 330K | 6K | 4.69M | 2.47M | 3.28M |
| Total Current Liabilities | 3.4M | 7.19M | 14.04M | 10.24M | 8.72M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 13K | 2K | 0 | 0 | 170K |
| Total Non-current Liabilities | 13K | 2K | 0 | 0 | 170K |
| Total Liabilities | 3.41M | 7.19M | 14.04M | 10.24M | 8.89M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (47.38M) | (89.72M) | (154.46M) | (205.78M) | (240.95M) |
| Accumulated OCI | (27K) | (374K) | 275K | 31K | 57K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 61.91M | 95.37M | 124.7M | 81.85M | 53.06M |
| Total Debt | 0 | 53K | 0 | 0 | 0 |
| Net Debt | (12.1M) | (27.17M) | (15.65M) | (21.35M) | (19.94M) |
AN2 Therapeutics, Inc.
NASDAQ:ANTX
Intrinsic Alpha fair value
Locked
Current Price
$4.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.